Pfizer Updates Registered Securities on NYSE
Ticker: PFE · Form: 8-K · Filed: Jan 30, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.05 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, securities-registration, 8-K
TL;DR
**Pfizer just filed a routine 8-K updating its listed securities, no big news.**
AI Summary
Pfizer Inc. filed an 8-K on January 30, 2024, to update its registered securities, specifically its Common Stock ($0.05 par value) and 1.000% Notes due 2027. Both are listed on the New York Stock Exchange under trading symbols PFE and PFE27, respectively. This filing is a routine update, indicating no immediate operational or financial changes, but it confirms the company's current capital structure and its compliance with SEC reporting requirements, which is important for investors tracking the company's financial health and transparency.
Why It Matters
This filing confirms Pfizer's listed securities, providing transparency on its capital structure and ensuring compliance, which is crucial for investor confidence and market stability.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational information, posing minimal risk.
Analyst Insight
A smart investor would recognize this as a routine compliance filing, not indicative of any immediate operational or financial changes, and would continue to monitor for more substantive news or financial reports.
Key Numbers
- $0.05 — Common Stock Par Value (The stated par value for each share of Pfizer's common stock.)
- 1.000% — Notes Due 2027 Interest Rate (The annual interest rate for Pfizer's notes maturing in 2027.)
Key Players & Entities
- PFIZER INC (company) — the registrant filing the 8-K
- New York Stock Exchange (company) — the exchange where Pfizer's securities are registered
- $0.05 (dollar_amount) — par value of Pfizer's Common Stock
- 1.000% (dollar_amount) — interest rate of Pfizer's Notes due 2027
- 2027 (date) — maturity year of Pfizer's Notes
Forward-Looking Statements
- Pfizer will continue to maintain its listing on the New York Stock Exchange for its common stock and notes. (PFIZER INC) — high confidence, target: 2025-01-30
FAQ
What is the purpose of this 8-K filing by Pfizer Inc.?
The purpose of this 8-K filing by Pfizer Inc. on January 30, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' specifically updating the securities registered pursuant to Section 12(b) of the Act.
Which specific securities of Pfizer Inc. are mentioned as registered in this filing?
The filing specifically mentions 'Common Stock, $0.05 par value' and '1.000% Notes due 2027' as registered securities.
On which exchange are Pfizer Inc.'s registered securities traded?
Both the Common Stock ($0.05 par value) and the 1.000% Notes due 2027 of Pfizer Inc. are registered and traded on the New York Stock Exchange.
What are the trading symbols for Pfizer Inc.'s registered securities mentioned in the filing?
The trading symbol for the Common Stock, $0.05 par value, is PFE, and the trading symbol for the 1.000% Notes due 2027 is PFE27.
What is the par value of Pfizer Inc.'s Common Stock as stated in this 8-K?
The par value of Pfizer Inc.'s Common Stock, as stated in this 8-K, is $0.05.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-30 08:04:28
Key Financial Figures
- $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange
Filing Documents
- pfe-20240130.htm (8-K) — 34KB
- pfe-12312023xex99.htm (EX-99) — 1509KB
- pfizerlogo.jpg (GRAPHIC) — 38KB
- 0000078003-24-000017.txt ( ) — 1844KB
- pfe-20240130.xsd (EX-101.SCH) — 3KB
- pfe-20240130_def.xml (EX-101.DEF) — 15KB
- pfe-20240130_lab.xml (EX-101.LAB) — 30KB
- pfe-20240130_pre.xml (EX-101.PRE) — 16KB
- pfe-20240130_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On January 30, 2024, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for fourth-quarter and full-year 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description Exhibit 99 Press Release of Pfizer Inc. dated January 30, 2024 , reporting Pfizer's financial results for fourth-quarter and full-year 2023. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. EXHIBIT INDEX Exhibit No. Description 99 Press Release of Pfizer Inc. dated January 30, 2024, reporting Pfizer's financial results for fourth-quarter and full-year 2023. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: January 30, 2024